PALI
USDPalisade Bio Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.910
Kõrge
$1.970
Madal
$1.822
Maht
1.22M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
259.3M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
8.45M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA,
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients
Seotud aktsiad
WEA
Western Asset Bond Fund Share of Beneficial Interest
LBRDP
Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock
GGG
Graco Inc.
DLHC
DLH Holdings Corp.
ALGS
Aligos Therapeutics Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.